Skip to main content

Table 1 Brain volume changes in RRMS patients treated with IFN β-1a SC tiw and HCs over time

From: Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

  Baseline to 12 weeks 12 to 24 weeks Baseline to 24 weeks
Patients HCs Patients HCs Patients HCs
n (missinga) 23 (0) 15 (0) 21 (2) 14 (1) 21 (2) 14 (1)
Percent change in whole brain (%)
 Mean (SD) –0.95 (1.712) 0.24 (1.068) –0.08 (1.358) –0.32 (1.500) –0.91 (1.880) 0.01 (0.885)
 Median –0.90 0.33 0.07 –0.02 –0.63 0.05
 Min, max –4.7, 2.8 –2.0, 1.7 –2.8, 2.6 –3.6, 2.2 –5.1, 2.4 –1.2, 1.8
P valueb 0.030 0.359 0.960 0.626 0.051 0.952
 Adjusted P-valueb,c NS NS NS NS NS NS
P-valued 0.015 0.702 0.071
 Adjusted P-valuec,d NS NS NS
 Adjusted P-valuec,e NS/NS  
Percent change in gray matter (%)
 Mean (SD) –1.52 (2.406) 0.01 (2.415) –0.46 (3.109) –0.60 (2.189) –1.66 (1.836) –0.51 (2.472)
 Median –1.89 0.80 –1.20 –0.72 –1.24 –1.31
 Min, max –6.3, 2.3 –3.7, 3.7 –6.3, 9.4 –4.4, 2.5 –5.9, 1.7 –4.5, 5.1
P-valueb 0.004 0.934 0.176 0.426 <0.001 0.268
 Adjusted P-valueb,c 0.0286 NS NS NS 0.0016 NS
P-valued 0.093 0.778 0.342
 Adjusted P-valuec,d NS NS NS
 Adjusted P-valuec,e NS/NS  
Percent change in white matter (%)
 Mean (SD) –0.41 (2.159) 0.51 (1.940) 0.30 (2.991) –0.03 (1.985) –0.21 (3.202) 0.58 (2.461)
 Median –0.63 0.69 0.93 0.50 0.08 0.95
 Min, max –5.4, 3.5 –5.1, 3.0 –6.5, 7.4 –3.4, 2.7 –5.9, 8.4 –4.5, 3.6
P-valueb 0.390 0.107 0.626 0.952 0.933 0.463
 Adjusted P-valueb,c NS NS NS NS NS NS
P-valued 0.093 0.630 0.309
 Adjusted P-valuec,d NS NS NS
 Adjusted P-valuec,e NS/NS  
  1. aFailed analysis or missing MRI at Week 24
  2. bFor the difference from zero within groups from the Wilcoxon signed-rank test
  3. cAdjusted for multiple comparisons with the Holm-Bonferroni correction; NS denotes adjusted P-values ≥ 0.05
  4. dFor the difference between IFN β-1a SC tiw and HCs from the Wilcoxon rank-sum test
  5. eFor the difference between the first 12 weeks and the second 12 weeks within groups from the Wilcoxon signed-rank test (P-value for patients/HCs)
  6. GM gray matter, HC healthy control; max: maximum; min: minimum, NS non-significant, SD standard deviation